Novo Nordisk said the FDA approved the marketing of Novartis tablets as oral GLP-1. The company's shares rose 6.6% after the market. It is the first oral GLP-1 receptor agonist approved for weight management. The approval is based on the OASIS test program and the SELECT test. In the OASIS 4 trial, 25 mg of simeglutide was taken orally once daily, with an average weight loss of 16.6%. The weight loss effect achieved by taking this tablet is similar to that of injectable norovalerin 2.4 mg. It is expected to be available in the US in early January 2026; it has applied for listing with the European Medicines Agency and other regulators in the second half of 2025.

Novo Nordisk said the FDA approved the marketing of Novartis tablets as oral GLP-1. The company's shares rose 6.6% after the market. It is the first oral GLP-1 receptor agonist approved for weight management. The approval is based on the OASIS test program and the SELECT test. In the OASIS 4 trial, 25 mg of simeglutide was taken orally once daily, with an average weight loss of 16.6%. The weight loss effect achieved by taking this tablet is similar to that of injectable norovalerin 2.4 mg. It is expected to be available in the US in early January 2026; it has applied for listing with the European Medicines Agency and other regulators in the second half of 2025.